Resistant gram-positive organisms.
Antimicrobial resistance in Gram-positive bacteria has reemerged in the last decade as a major clinical problem. Methicillin-resistant staphylococci, penicillin-resistant pneumococci, and enterococci resistant to penicillin, vancomycin, and/or gentamicin have become new considerations in the selection of therapy. Both mutation and acquisition of new DNA on either the chromosome or plasmids can be responsible for resistance in Gram-positive species. Because therapies are often limited, renewed efforts are needed to understand the epidemiology in order to effect control.
Schaberg
D R
DR
Department of Medicine, University of Tennessee-Memphis.
D004352:Drug Resistance, Microbial / Q000235:genetics; D013293:Enterococcus faecalis / Q000235:genetics; D016984:Enterococcus faecium / Q000235:genetics; D015964:Gene Expression Regulation, Bacterial; D006094:Gram-Positive Bacteria / Q000235:genetics; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology*; D006801:Humans; D009154:Mutation; D015995:Prevalence; D011815:R Factors; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D013211:Staphylococcus aureus / Q000235:genetics; D013290:Streptococcal Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000235:genetics